Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 514
- Registration Number
- NCT05804032
- Locations
- 🇦🇹
Phyrn-Eisenwurzen Klinikum Steyr, Steyr, Austria
🇦🇹Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz, Salzburg, Austria
🇩🇪Charité, III. Medizinische Abteilung (Hämatologie/Onkologie), Berlin, Germany
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05736419
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT05695508
- Locations
- 🇩🇪
Charité University Medicin Berlin, Berlin, Germany
🇩🇪Clinic Chemnitz gGmbH, Chemnitz, Germany
🇩🇪University Clinic Technical University Dresden, Dresden, Germany
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 100
- Registration Number
- NCT05665140
- Locations
- 🇩🇪
Heloisklinikum Berlin Buch GmbH, Berlin, Germany
🇩🇪Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin, Bielefeld, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05599880
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Guri-si, Korea, Republic of
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹Uls Gaia Espinho, Vila Nova de Gaia, Portugal
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05564052
- Locations
- 🇹🇷
Ondokuz Mayis University, Atakum, Turkey
🇧🇷Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil
🇧🇷Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia, Brasilia, Brazil
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 510
- Registration Number
- NCT05561387
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Saint Anthony's Health, Alton, Illinois, United States
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 480
- Registration Number
- NCT05558319
- Locations
- 🇪🇸
Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.